An Insight into FDA Approved Antibody-Drug Conjugates for Cancer Therapy.
Molecules
; 26(19)2021 Sep 27.
Article
in English
| MEDLINE | ID: covidwho-1438677
ABSTRACT
The large number of emerging antibody-drug conjugates (ADCs) for cancer therapy has resulted in a significant market 'boom', garnering worldwide attention. Despite ADCs presenting huge challenges to researchers, particularly regarding the identification of a suitable combination of antibody, linker, and payload, as of September 2021, 11 ADCs have been granted FDA approval, with eight of these approved since 2017 alone. Optimism for this therapeutic approach is clear, despite the COVID-19 pandemic, 2020 was a landmark year for deals and partnerships in the ADC arena, suggesting that there remains significant interest from Big Pharma. Herein we review the enthusiasm for ADCs by focusing on the features of those approved by the FDA, and offer some thoughts as to where the field is headed.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Immunoconjugates
/
Neoplasms
/
Antineoplastic Agents
Limits:
Animals
/
Humans
Country/Region as subject:
North America
Language:
English
Journal subject:
Biology
Year:
2021
Document Type:
Article
Affiliation country:
Molecules26195847
Similar
MEDLINE
...
LILACS
LIS